Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy.

Eli Lilly and Company (NYSE:LLY) may be affected by the CVS formulary change considering it could change how its medication, Zepbound, is viewed when compared to Wegovy. That said, despite possible ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Detailed price information for Unitedhealth Group Inc (UNH-N) from The Globe and Mail including charting and trades.

STORY: Eli Lilly said Monday it will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying ...

NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.

Novo Nordisk A/S shares are staging a comeback after a tumultuous year for the maker of Ozempic and Wegovy. The stock is up ...

Wall Street's major averages plummeted on Friday after Israel and Iran traded missile strikes and stoked concerns of an ...

Eli Lilly will start selling the two highest doses of its popular weight-loss drug Zepbound directly to customers online in ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...